Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach

No abstract is available for this paper.

• Publication year

  2008

• Venue

  European Journal of Human Genetics

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/ejhg.2008.13PMID 18285836PMCID PMC3905962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Automated array-CGH optimized for archival formalin-fixed, paraffin-embedded tumor material

  2007cited by this paper
• Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.

  2007cited by this paper
• Functional assays for BRCA1 and BRCA2.

  2007cited by this paper
• A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.

  2007cited by this paper
• Functional Impact of Missense Variants in BRCA1 Predicted by Supervised Learning

  2006cited by this paper
• Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.

  2006cited by this paper
• Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles

  2006cited by this paper
• Cancer risk assessment at the atomic level.

  2006cited by this paper
• Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.

  2006cited by this paper
• Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.

  2005cited by this paper
• A multiplex PCR predictor for aCGH success of FFPE samples

  2005cited by this paper
• Classification of BRCA1 missense variants of unknown clinical significance

  2005cited by this paper
• A statistical approach for array CGH data analysis

  2005cited by this paper
• Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral

  2005cited by this paper
• DNA Damage-Induced Cell Cycle Checkpoint Control Requires CtIP, a Phosphorylation-Dependent Binding Partner of BRCA1 C-Terminal Domains

  2004cited by this paper
• Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer

  2004cited by this paper
• Coot: model-building tools for molecular graphics.

  2004cited by this paper
• Structure-Based Assessment of Missense Mutations in Human BRCA1

  2004cited by this paper
• Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2.

  2004cited by this paper
• Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1

  2004cited by this paper
• Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.

  2004cited by this paper
• Structural Consequences of a Cancer-causing BRCA1-BRCT Missense Mutation*

  2003cited by this paper
• A full-likelihood method for the evaluation of causality of sequence variants from family data.

  2003cited by this paper
• SIFT: predicting amino acid changes that affect protein function

  2003cited by this paper
• POVScript+: a program for model and data visualization using persistence of vision ray-tracing

  2003cited by this paper
• BRCT Repeats As Phosphopeptide-Binding Modules Involved in Protein Targeting

  2003cited by this paper
• Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.

  2002cited by this paper
• Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer

  2002cited by this paper
• Diagnosis of multiple cancer types by shrunken centroids of gene expression

  2002cited by this paper
• The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

  2002cited by this paper
• Corresponding authors:

  2002cited by this paper
• Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.

  2001cited by this paper
• BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.

  2001cited by this paper
• Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.

  2000cited by this paper
• Genetic analysis of BRCA1 function in a defined tumor cell line.

  1999cited by this paper
• The C-terminal (BRCT) Domains of BRCA1 Interact in Vivo with CtIP, a Protein Implicated in the CtBP Pathway of Transcriptional Repression*

  1998cited by this paper
• [20] Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• Refinement of macromolecular structures by the maximum-likelihood method.

  1997cited by this paper
• MOLREP: an Automated Program for Molecular Replacement

  1997cited by this paper
• Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• Evidence for a transcriptional activation function of BRCA1 C-terminal region.

  1996cited by this paper
• Correlation of two-hybrid affinity data with in vitro measurements

  1995cited by this paper
• High allele loss rates at I7q I2‐q2I in breast and ovarian tumors from BRCAI‐linked families

  1995cited by this paper
• High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium.

  1995cited by this paper
• Allele losses in the region 17q12–21 in familial breast and ovarian cancer involve the wild–type chromosome

  1992cited by this paper
• Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons

  1991cited by this paper
• PCR protocols — A guide to methods and applications

  1990cited by this paper
• A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor.

  1985cited by this paper

• Screening of Germline BRCA1 and BRCA2 Variants in Nigerian Breast Cancer Patients

  2025cites this paper
• Metal organic framework supported Surface modification of synthesized Nickel/Nickel Oxide Nanoparticles via Controlled PEGylation For Cytotoxicity Profile against MCF-7 Breast Cancer Cell lines via Docking analysis

  2023cites this paper
• Structural implications of amyloidogenic rare variants Ser282Leu and Gln356Arg identified in h‐BRCA1

  2023cites this paper
• Computational approaches for predicting variant impact: An overview from resources, principles to applications

  2022cites this paper
• Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology

  2021cites this paper
• One-Pot Surface Modification of β-Cu2O NPs for Biocatalytic Performance against A-549 Lung Carcinoma Cell Lines through Docking Analysis

  2021cites this paper
• LAHMA: structure analysis through local annotation of homology-matched amino acids

  2021cites this paper
• Investigation into the origins of an ancient BRCA1 founder mutation identified among Chinese families in Singapore

  2020cites this paper
• Prediction of -association in hereditary non- breast carcinomas with array-CGH

  2020cites this paper
• Structure‐Guided Synthesis and Evaluation of Small‐Molecule Inhibitors Targeting Protein–Protein Interactions of BRCA1 tBRCT Domain

  2019cites this paper
• Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort

  2019cites this paper
• Investigation of structural and biological properties of N-heterocyclic carbene silver(I) and palladium(II) complexes

  2018cites this paper
• BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far.

  2018cites this paper
• Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance

  2018cites this paper
• A comparison of cosegregation analysis methods for the clinical setting

  2018cites this paper
• BRCA1/2 germline missense mutations: a systematic review

  2017cites this paper
• Síndrome de cáncer de mama y ovario hereditario: Estudio in vitro de variantes BRCA1 y BRCA2 de significado biológico desconocido y búsqueda de nuevos genes responsables de este síndrome

  2016cites this paper
• The Role of BRCT-Containing Proteins BRCA1 and PAXIP1 in Cancer

  2015cites this paper
• BRCA1 Circos: a visualisation resource for functional analysis of missense variants

  2015cites this paper
• Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival

  2014cites this paper
• Structural basis for the BRCA1 BRCT interaction with the proteins ATRIP and BAAT1.

  2013cites this paper
• Prognostic value of CtIP/RBBP8 expression in breast cancer

  2013cites this paper
• Pathogenicity of Mutations Discovered in BRCA1 BRCT Domains is Characterized by Destabilizing the Hydrophobic Interactions

  2012cites this paper
• Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer

  2012cites this paper
• Full-Exon Pyrosequencing Screening of BRCA Germline Mutations in Mexican Women with Inherited Breast and Ovarian Cancer

  2012cites this paper
• Prediction of "BRCAness" in breast cancer by array comparative genomic hybridization

  2012cites this paper
• The BRCT Signaling 'Landscape': Emerging Concepts and Implications in Tumorigenesis and Cancer Diagnostics

  2012cites this paper
• Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH

  2012cites this paper
• SKEMPI: a Structural Kinetic and Energetic database of Mutant Protein Interactions and its use in empirical models

  2012cites this paper
• Classification of missense substitutions in the BRCA genes: A database dedicated to Ex‐UVs

  2012cites this paper
• Impact of BRCA1 BRCT Domain Missense Substitutions on Phosphopeptide Recognition

  2011cites this paper
• Mutations in the BRCT binding site of BRCA1 result in hyper-recombination

  2011cites this paper
• On the role of electrostatics in protein–protein interactions

  2011cites this paper
• Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness

  2011cites this paper
• Novel Roles for 185delAG Mutant BRCA1 in Ovarian Cancer Pathology

  2010cites this paper
• Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models.

  2010cites this paper
• Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis

  2010cites this paper
• BRCA1 16 years later: risk‐associated BRCA1 mutations and their functional implications

  2010cites this paper
• BRCA Gene Structure and Function in Tumor Suppression: A Repair-Centric Perspective

  2010cites this paper
• Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.

  2010influential citation
• DNA ligase PCNA

  2009cites this paper
• puBlICatIons du personnel du CIrC 2008-2009

  2009cites this paper
• Positional analyses of BRCA 1-dependent expression in Saccharomyces cerevisiae

  2009cites this paper
• Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.

  2009cites this paper
• Characterisation of gene expression profiles of yeast cells expressing BRCA1 missense variants.

  2009cites this paper
• Unclassified Variants in the Breast Cancer Susceptibility Genes BRCA1 and BRCA2

  2009cites this paper
• Characterization of cancer‐linked BRCA1‐BRCT missense variants and their interaction with phosphoprotein targets

  2009cites this paper
• The BARD1 C-Terminal Domain Structure and Interactions with Polyadenylation Factor CstF-50

  2008cites this paper
• Positional analyses of BRCA1-dependent expression in Saccharomyces cerevisiae

  2008cites this paper
• Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH

  2008cites this paper
• Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance

  2008cites this paper
• Only about 25% of familial breast cancer is explained by mutations in brca1 and brca2, fewer by moderate penetrance genes like p53, pten, chek2, atm and palb2 and an unknown fraction by common variants of genes with low penetrance

  2008cites this paper